{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:56:47Z","timestamp":1793087807915,"version":"4.5.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41571-026-01120-7","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:30:53Z","timestamp":1770118253000},"page":"297-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7192","authenticated-orcid":false,"given":"Soraia","family":"Lobo-Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2906","authenticated-orcid":false,"given":"Stephen J.","family":"Luen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"1120_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1120_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","volume":"18","author":"HA Azim","year":"2012","unstructured":"Azim, H. A. et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin. Cancer Res. 18, 1341\u20131351 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 159\u2013182 (2024).","journal-title":"Ann. Oncol."},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","volume":"34","author":"SJ Luen","year":"2023","unstructured":"Luen, S. J. et al. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann. Oncol. 34, 397\u2013409 (2023).","journal-title":"Ann. Oncol."},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","volume":"33","author":"S Paluch-Shimon","year":"2022","unstructured":"Paluch-Shimon, S. et al. ESO\u2013ESMO fifth International Consensus Guidelines for Breast Cancer in Young Women (BCY5). Ann. Oncol. 33, 1097\u20131118 (2022).","journal-title":"Ann. Oncol."},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 371, 107\u2013118 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis, P. A. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N. Engl. J. Med. 379, 122\u2013137 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J. Clin. Oncol. 41, 1376\u20131382 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.505","volume":"43","author":"PA Francis","year":"2025","unstructured":"Francis, P. A. et al. 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T) + OFS [abstract]. J. Clin. Oncol. 43, 505 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck, N. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann. Oncol. 32, 1571\u20131581 (2021).","journal-title":"Ann. Oncol."},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston, S. R. D. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 24, 77\u201390 (2023).","journal-title":"Lancet Oncol."},{"key":"1120_CR13","doi-asserted-by":"publisher","first-page":"S1256","DOI":"10.1016\/j.annonc.2023.10.007","volume":"34","author":"N Harbeck","year":"2023","unstructured":"Harbeck, N. et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2\u2212, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes [abstract LBA17]. Ann. Oncol. 34, S1256 (2023).","journal-title":"Ann. Oncol."},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi, P. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J. Clin. Oncol. 42, 987\u2013993 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104748","volume":"10","author":"N Harbeck","year":"2025","unstructured":"Harbeck, N. et al. Efficacy and safety of abemaciclib in younger patients with early breast cancer in the monarchE trial [abstract 194P]. TESMO Open 10, 104748 (2025).","journal-title":"ESMO Open"},{"key":"1120_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231178125","volume":"15","author":"DJ Slamon","year":"2023","unstructured":"Slamon, D. J. et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib\u2009+\u2009endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2\u2212 early breast cancer. Ther. Adv. Med. Oncol. 15, 17588359231178125 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1120_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","volume":"41","author":"DJ Slamon","year":"2023","unstructured":"Slamon, D. J. et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial [abstract]. J. Clin. Oncol. 41, LBA500 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med. 390, 1080\u20131091 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.516","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky, K. et al. Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: analysis across menopausal status and age [abstract]. J. Clin. Oncol. 43, 516 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","volume":"36","author":"GN Hortobagyi","year":"2025","unstructured":"Hortobagyi, G. N. et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann. Oncol. 36, 149\u2013157 (2025).","journal-title":"Ann. Oncol."},{"key":"1120_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","volume":"11","author":"PA Fasching","year":"2025","unstructured":"Fasching, P. A. et al. Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol. 11, 1364\u20131372 (2025).","journal-title":"JAMA Oncol."},{"key":"1120_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53331","volume":"7","author":"S Xu","year":"2024","unstructured":"Xu, S., Murtagh, S., Han, Y., Wan, F. & Toriola, A. T. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw. Open. 7, e2353331 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","volume":"35","author":"P Saha","year":"2017","unstructured":"Saha, P. et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. J. Clin. Oncol. 35, 3113\u20133122 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge, A. H. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J. Clin. Oncol. 34, 3308\u20133314 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.breast.2021.12.006","volume":"61","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J., Kim, S., Freedman, R. A. & Partridge, A. H. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: a U.S. SEER database analysis. Breast 61, 77\u201383 (2022).","journal-title":"Breast"},{"key":"1120_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.42663","volume":"7","author":"DS Shin","year":"2024","unstructured":"Shin, D. S. et al. Age and late recurrence in young patients with ER-positive, ERBB2-negative breast cancer. JAMA Netw. Open. 7, e2442663 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.24.01131","volume":"43","author":"E Dumas","year":"2025","unstructured":"Dumas, E. et al. Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study. J. Clin. Oncol. 43, 1863\u20131874 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR28","unstructured":"World Health Organization. Menopause. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/menopause (2024)."},{"key":"1120_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF01805762","volume":"10","author":"LE Rutqvist","year":"1987","unstructured":"Rutqvist, L. E. et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res. Treat. 10, 255\u2013266 (1987).","journal-title":"Breast Cancer Res. Treat."},{"key":"1120_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.505","volume":"42","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky, K. et al. Correlation of serum anti-M\u00fcllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER) [abstract]. J. Clin. Oncol. 42, 505 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly, M. B. et al. NCCN Guidelines\u00ae Insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024. J. Natl Compr. Canc Netw. 21, 1000\u20131010 (2023).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-21-2572","volume":"28","author":"AG Waks","year":"2022","unstructured":"Waks, A. G. et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin. Cancer Res. 28, 2339\u20132348 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.31427","volume":"7","author":"Z Rezoug","year":"2024","unstructured":"Rezoug, Z. et al. Universal genetic testing for newly diagnosed invasive breast cancer. JAMA Netw. Open. 7, e2431427 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1120_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson, E. R. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19, 169\u2013180 (2018).","journal-title":"Lancet Oncol."},{"key":"1120_CR35","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer, C. E. et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann. Oncol. 33, 1250\u20131268 (2022).","journal-title":"Ann. Oncol."},{"key":"1120_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jamaoncol.2015.5941","volume":"2","author":"SM Rosenberg","year":"2016","unstructured":"Rosenberg, S. M. et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2, 730\u2013736 (2016).","journal-title":"JAMA Oncol."},{"key":"1120_CR38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","volume":"35","author":"L Arecco","year":"2024","unstructured":"Arecco, L. et al. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. Ann. Oncol. 35,\u00a0792\u2013804\u00a0(2024).","journal-title":"Ann. Oncol."},{"key":"1120_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.10503","volume":"42","author":"M Lambertini","year":"2024","unstructured":"Lambertini, M. et al. Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: results from an international cohort study [abstract]. J. Clin. Oncol. 42, 10503 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR40","doi-asserted-by":"publisher","unstructured":"Safonov, A. et al. Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.02.05.578934 (2024).","DOI":"10.1101\/2024.02.05.578934"},{"key":"1120_CR41","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1021","volume":"42","author":"NM Tung","year":"2024","unstructured":"Tung, N. M. et al. TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2 [abstract]. J. Clin. Oncol. 42, 1021 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR43","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT007","volume":"82","author":"TA Yap","year":"2022","unstructured":"Yap, T. A. et al. PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations [abstract]. Cancer Res. 82, CT007 (2022).","journal-title":"Cancer Res."},{"key":"1120_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"1120_CR45","unstructured":"Australian New Zealand Clinical Trials Registry. ANZCTR https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12623000657628 (2024)."},{"key":"1120_CR46","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-024-08377-x","volume":"638","author":"KE Houlahan","year":"2025","unstructured":"Houlahan, K. E. et al. Complex rearrangements fuel ER+ and HER2+ breast tumours. Nature 638, 510\u2013518 (2025).","journal-title":"Nature"},{"key":"1120_CR47","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41586-023-06057-w","volume":"618","author":"JJ-K Lee","year":"2023","unstructured":"Lee, J. J.-K. et al. ER\u03b1-associated translocations underlie oncogene amplifications in breast cancer. Nature 618, 1024\u20131032 (2023).","journal-title":"Nature"},{"key":"1120_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0504-3","volume":"13","author":"HA Azim","year":"2015","unstructured":"Azim, H. A., Nguyen, B., Broh\u00e9e, S., Zoppoli, G. & Sotiriou, C. Genomic aberrations in young and elderly breast cancer patients. BMC Med. 13, 266 (2015).","journal-title":"BMC Med."},{"key":"1120_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-023-07179-5","volume":"204","author":"D Blansky","year":"2024","unstructured":"Blansky, D. et al. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Res. Treat. 204, 181\u2013185 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"1120_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.clbc.2024.07.008","volume":"24","author":"AL Heeke","year":"2024","unstructured":"Heeke, A. L. et al. The genomic landscape of breast cancer in young and older women. Clin. Breast Cancer 24, 630\u2013638.e3 (2024).","journal-title":"Clin. Breast Cancer"},{"key":"1120_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04129-4","volume":"9","author":"Z Kan","year":"2018","unstructured":"Kan, Z. et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat. Commun. 9, 1725 (2018).","journal-title":"Nat. Commun."},{"key":"1120_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860\u2013867 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR53","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","volume":"26","author":"MV Dieci","year":"2015","unstructured":"Dieci, M. V. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann. Oncol. 26, 1698\u20131704 (2015).","journal-title":"Ann. Oncol."},{"key":"1120_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"1120_CR55","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/jnci\/djae178","volume":"116","author":"D Massa","year":"2024","unstructured":"Massa, D. et al. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer. J. Natl Cancer Inst. 116, 1914\u20131927 (2024).","journal-title":"J. Natl Cancer Inst."},{"key":"1120_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00543-0","volume":"9","author":"L Voorwerk","year":"2023","unstructured":"Voorwerk, L. et al. Immune landscape of breast tumors with low and intermediate estrogen receptor expression. NPJ Breast Cancer 9, 39 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"1120_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00223-x","volume":"7","author":"G Griguolo","year":"2021","unstructured":"Griguolo, G. et al. Immune microenvironment and intrinsic subtyping in hormone receptor-positive\/HER2-negative breast cancer. NPJ Breast Cancer 7, 12 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1120_CR58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.558","volume":"42","author":"G Griguolo","year":"2024","unstructured":"Griguolo, G. et al. Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)\/HER2-negative (HER2-) early breast cancer (BC): a translational analysis of two multicentric neoadjuvant trials [abstract]. J. Clin. Oncol. 42, 558 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113399","volume":"195","author":"F Miglietta","year":"2023","unstructured":"Miglietta, F. et al. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive\/HER2-negative breast cancer: analysis of four prospective studies. Eur. J. Cancer 195, 113399 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1120_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674192","volume":"12","author":"J Goldberg","year":"2021","unstructured":"Goldberg, J. et al. The immunology of hormone receptor positive breast cancer. Front. Immunol. 12, 674192 (2021).","journal-title":"Front. Immunol."},{"key":"1120_CR61","volume":"25","author":"G Oner","year":"2020","unstructured":"Oner, G. et al. The immunologic aspects in hormone receptor positive breast cancer. Cancer Treat. Res. Commun. 25, 100207 (2020).","journal-title":"Cancer Treat. Res. Commun."},{"key":"1120_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1176-2","volume":"21","author":"M Sobral-Leite","year":"2019","unstructured":"Sobral-Leite, M. et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res. 21, 90 (2019).","journal-title":"Breast Cancer Res."},{"key":"1120_CR63","doi-asserted-by":"publisher","first-page":"v60","DOI":"10.1093\/annonc\/mdz240.011","volume":"30","author":"T O\u2019Meara","year":"2019","unstructured":"O\u2019Meara, T. et al. Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancers [abstract 185PD]. Ann. Oncol. 30, v60\u2013v61 (2019).","journal-title":"Ann. Oncol."},{"key":"1120_CR64","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-19-0173","volume":"25","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clin. Cancer Res. 25, 4644\u20134655 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.102","volume":"41","author":"DM Wolf","year":"2023","unstructured":"Wolf, D. M. et al. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): evaluation of immune subtyping in the response predictive subtypes (RPS) [abstract]. J. Clin. Oncol. 41, 102 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR66","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2023.41.16_suppl.505","volume":"41","author":"ME Tesch","year":"2023","unstructured":"Tesch, M. E. et al. Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+\/HER2- breast cancer (BC) [abstract]. J. Clin. Oncol. 41, 505\u2013505 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR67","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/jnci\/94.19.1433","volume":"94","author":"RR Love","year":"2002","unstructured":"Love, R. R. & Philips, J. Oophorectomy for breast cancer: history revisited. J. Natl Cancer Inst. 94, 1433\u20131434 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"1120_CR68","first-page":"153","volume":"15","author":"GT Beatson","year":"1896","unstructured":"Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans. Med. Chir. Soc. Edinb. 15, 153\u2013179 (1896).","journal-title":"Trans. Med. Chir. Soc. Edinb."},{"key":"1120_CR69","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano, G. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann. Oncol. 34, 970\u2013986 (2023).","journal-title":"Ann. Oncol."},{"key":"1120_CR70","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","volume":"23","author":"S Noguchi","year":"2016","unstructured":"Noguchi, S. et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer 23, 771\u2013779 (2016).","journal-title":"Breast Cancer"},{"key":"1120_CR71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","volume":"126","author":"N Masuda","year":"2011","unstructured":"Masuda, N. et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat. 126, 443\u2013451 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"1120_CR72","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.3390\/curroncol31080314","volume":"31","author":"N LeVasseur","year":"2024","unstructured":"LeVasseur, N., Manna, M. & Jerzak, K. J. An overview of long-acting GnRH agonists in premenopausal breast cancer patients: survivorship challenges and management. Curr. Oncol. 31, 4209\u20134224 (2024).","journal-title":"Curr. Oncol."},{"key":"1120_CR73","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Acute Lymphoblastic Leukemia https:\/\/www.nccn.org\/guidelines\/guidelines-detail (2025)."},{"key":"1120_CR74","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1200\/JCO.18.00296","volume":"37","author":"S Dellapasqua","year":"2019","unstructured":"Dellapasqua, S. et al. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial. J. Clin. Oncol. 37, 386\u2013395 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000485","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2000","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst. Rev. CD000485 https:\/\/doi.org\/10.1002\/14651858.CD000485 (2000).","journal-title":"Cochrane Database Syst. Rev. CD000485"},{"key":"1120_CR76","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","volume":"348","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1996","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348, 1189\u20131196 (1996).","journal-title":"Lancet"},{"key":"1120_CR77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.503","volume":"41","author":"RG Gray","year":"2023","unstructured":"Gray, R. G. et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials [abstract]. J. Clin. Oncol. 41, 503 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR78","unstructured":"US Food and Drug Administration. Tamoxifen. FDA https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=070929 (2026)."},{"key":"1120_CR79","unstructured":"Medicines and Healthcare Products Regulatory Agency. Nolvadex. MHRA https:\/\/products.mhra.gov.uk\/search\/?search=nolvadex&page=1&doc=Spc&rerouteType=0 (2026)."},{"key":"1120_CR80","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2002.11.101","volume":"20","author":"B Fisher","year":"2002","unstructured":"Fisher, B. et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. 20, 4141\u20134149 (2002).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher, B. et al. A Randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320, 479\u2013484 (1989).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR82","unstructured":"Fisher, B. & Redmond, C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant breast and bowel project. J. Natl Cancer Inst. Monogr. 105\u2013116 (1992)."},{"key":"1120_CR83","first-page":"171","volume":"2","author":"[No authors listed]","year":"1987","unstructured":"[No authors listed] Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2, 171\u2013175 (1987).","journal-title":"Lancet"},{"key":"1120_CR84","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684\u2013690 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"1120_CR85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.1996.356","volume":"74","author":"HJ Stewart","year":"1996","unstructured":"Stewart, H. J. et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br. J. Cancer 74, 297\u2013299 (1996).","journal-title":"Br. J. Cancer"},{"key":"1120_CR86","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805\u2013816 (2013).","journal-title":"Lancet"},{"key":"1120_CR87","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJM198812293192601","volume":"319","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1988","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl. J. Med. 319, 1681\u20131692 (1988).","journal-title":"New Engl. J. Med."},{"key":"1120_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339, 1\u201315 (1992).","journal-title":"Lancet"},{"key":"1120_CR89","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451\u20131467 (1998).","journal-title":"Lancet"},{"key":"1120_CR90","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687\u20131717 (2005).","journal-title":"Lancet"},{"key":"1120_CR91","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771\u2013784 (2011).","journal-title":"Lancet"},{"key":"1120_CR92","unstructured":"European Medicines Agency. Femara \u2013 referral. EMA https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/femara (2012)."},{"key":"1120_CR93","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith, I. E. & Dowsett, M. Aromatase inhibitors in breast cancer. New Engl. J. Med. 348, 2431\u20132442 (2003).","journal-title":"New Engl. J. Med."},{"key":"1120_CR94","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss, P. E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97, 1262\u20131271 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"1120_CR95","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","volume":"26","author":"PE Goss","year":"2008","unstructured":"Goss, P. E. et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J. Clin. Oncol. 26, 1948\u20131955 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR96","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/JCO.2010.34.4010","volume":"30","author":"H Jin","year":"2012","unstructured":"Jin, H., Tu, D., Zhao, N., Shepherd, L. E. & Goss, P. E. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J. Clin. Oncol. 30, 718\u2013721 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR97","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341\u20131352 (2015).","journal-title":"Lancet"},{"key":"1120_CR98","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679\u2013691 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR99","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.19.00126","volume":"38","author":"H-A Kim","year":"2020","unstructured":"Kim, H.-A. et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J. Clin. Oncol. 38, 434\u2013443 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR100","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1200\/JCO.23.00557","volume":"41","author":"SY Baek","year":"2023","unstructured":"Baek, S. Y. et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J. Clin. Oncol. 41, 4864\u20134871 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.506","volume":"43","author":"JM Ryu","year":"2025","unstructured":"Ryu, J. M. et al. Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor-positive breast cancer: results from the ASTRRA trial [abstract]. J. Clin. Oncol. 43, 506 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104085","volume":"10","author":"A Gravina","year":"2025","unstructured":"Gravina, A. et al. Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients. ESMO Open\u00a010, 104085 (2025).","journal-title":"ESMO Open"},{"key":"1120_CR103","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","volume":"23","author":"R Bradley","year":"2022","unstructured":"Bradley, R. et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 23, 382\u2013392 (2022).","journal-title":"Lancet Oncol."},{"key":"1120_CR104","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","volume":"22","author":"MA Franzoi","year":"2021","unstructured":"Franzoi, M. A. et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 22, e303\u2013e313 (2021).","journal-title":"Lancet Oncol."},{"key":"1120_CR105","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/j.clbc.2024.08.018","volume":"24","author":"N Zhang","year":"2024","unstructured":"Zhang, N. et al. Chemotherapy combined with endocrine therapy: old wine in a new bottle? Clin. Breast Cancer 24, e737\u2013e747 (2024).","journal-title":"Clin. Breast Cancer"},{"key":"1120_CR106","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14740338.2023.2203485","volume":"22","author":"Y Ergun","year":"2023","unstructured":"Ergun, Y., Ucar, G. & Akag\u00fcnd\u00fcz, B. Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systematic review and meta-analysis. Expert Opin. Drug Saf. 22, 313\u2013322 (2023).","journal-title":"Expert Opin. Drug Saf."},{"key":"1120_CR107","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1989.7.6.710","volume":"7","author":"CK Osborne","year":"1989","unstructured":"Osborne, C. K., Kitten, L. & Arteaga, C. L. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J. Clin. Oncol. 7, 710\u2013717 (1989).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR108","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1001\/jama.2015.17291","volume":"314","author":"M Lambertini","year":"2015","unstructured":"Lambertini, M. et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314, 2632\u20132640 (2015).","journal-title":"JAMA"},{"key":"1120_CR109","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","volume":"372","author":"HCF Moore","year":"2015","unstructured":"Moore, H. C. F. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N. Engl. J. Med. 372, 923\u2013932 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR110","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","volume":"28","author":"RCF Leonard","year":"2017","unstructured":"Leonard, R. C. F. et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann. Oncol. 28, 1811\u20131816 (2017).","journal-title":"Ann. Oncol."},{"key":"1120_CR111","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J. Clin. Oncol. 39, 1485\u20131505 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR112","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.18.01967","volume":"38","author":"O Pagani","year":"2020","unstructured":"Pagani, O. et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J. Clin. Oncol. 38, 1293\u20131303 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR113","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","volume":"36","author":"M Dowsett","year":"2018","unstructured":"Dowsett, M. et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J. Clin. Oncol. 36, 1941\u20131948 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR114","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-GS4-03","volume":"80","author":"I Sestak","year":"2020","unstructured":"Sestak, I. et al. Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study [abstract]. Cancer Res. 80, GS4-03 (2020).","journal-title":"Cancer Res."},{"key":"1120_CR115","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","volume":"4","author":"I Sestak","year":"2018","unstructured":"Sestak, I. et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 545\u2013553 (2018).","journal-title":"JAMA Oncol."},{"key":"1120_CR116","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdt494","volume":"25","author":"M Gnant","year":"2014","unstructured":"Gnant, M. et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 25, 339\u2013345 (2014).","journal-title":"Ann. Oncol."},{"key":"1120_CR117","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1158\/1078-0432.CCR-19-0376","volume":"25","author":"M Filipits","year":"2019","unstructured":"Filipits, M. et al. Prediction of distant recurrence using EndoPredict among women with ER+, HER2\u2212 node-positive and node-negative breast cancer treated with endocrine therapy only. Clin. Cancer Res. 25, 3865\u20133872 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR118","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/bjc.2013.671","volume":"109","author":"P Dubsky","year":"2013","unstructured":"Dubsky, P. et al. The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients. Br. J. Cancer 109, 2959\u20132964 (2013).","journal-title":"Br. J. Cancer"},{"key":"1120_CR119","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-07-5026","volume":"14","author":"X-J Ma","year":"2008","unstructured":"Ma, X.-J. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14, 2601\u20132608 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR120","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1158\/1078-0432.CCR-07-0310","volume":"13","author":"Z Wang","year":"2007","unstructured":"Wang, Z. et al. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin. Cancer Res. 13, 6327\u20136334 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR121","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","volume":"30","author":"JMS Bartlett","year":"2019","unstructured":"Bartlett, J. M. S. et al. Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen\u2014To Offer More? (aTTom) trial. Ann. Oncol. 30, 1776\u20131783 (2019).","journal-title":"Ann. Oncol."},{"key":"1120_CR122","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR123","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano, J. A. et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N. Engl. J. Med. 380, 2395\u20132405 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR124","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717\u2013729 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR125","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22, 476\u2013488 (2021).","journal-title":"Lancet Oncol."},{"key":"1120_CR126","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky, K. et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385, 2336\u20132347 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR127","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.annonc.2021.05.804","volume":"32","author":"MJ Piccart","year":"2021","unstructured":"Piccart, M. J. et al. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. Ann. Oncol. 32, 1077\u20131082 (2021).","journal-title":"Ann. Oncol."},{"key":"1120_CR128","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.2015.62.6630","volume":"34","author":"N Wolmark","year":"2016","unstructured":"Wolmark, N. et al. Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology\/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J. Clin. Oncol. 34, 2350\u20132358 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.511","volume":"42","author":"J O\u2019Shaughnessy","year":"2024","unstructured":"O\u2019Shaughnessy, J. et al. Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline [abstract]. J. Clin. Oncol. 42, 511 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR130","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS3-03","volume":"31","author":"N Chen","year":"2025","unstructured":"Chen, N. et al. Impact of anthracyclines in high genomic risk node-negative HR+\/HER2\u2212 breast cancer [abstract]. Clin. Cancer. Res. 31, GS3-03 (2025).","journal-title":"Clin. Cancer. Res."},{"key":"1120_CR131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.504","volume":"41","author":"LC Brown","year":"2023","unstructured":"Brown, L. C. et al. Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: a secondary analysis of the SOFT trial [abstract]. J. Clin. Oncol. 41, 504 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR132","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1200\/JCO.19.01959","volume":"38","author":"PD Poorvu","year":"2020","unstructured":"Poorvu, P. D. et al. Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-positive\/HER2-negative breast cancer. J. Clin. Oncol. 38, 725\u2013733 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR133","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamaoncol.2024.3044","volume":"10","author":"RM O\u2019Regan","year":"2024","unstructured":"O\u2019Regan, R. M. et al. Breast cancer index in premenopausal women with early-stage hormone receptor-positive breast cancer. JAMA Oncol. 10, 1379\u20131389 (2024).","journal-title":"JAMA Oncol."},{"key":"1120_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00188-3","volume":"6","author":"C Villarreal-Garza","year":"2020","unstructured":"Villarreal-Garza, C. et al. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer 6, 46 (2020).","journal-title":"NPJ Breast Cancer"},{"key":"1120_CR135","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.annonc.2024.08.178","volume":"35","author":"S Loi","year":"2024","unstructured":"Loi, S. et al. Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) in NATALEE [abstract 235MO]. Ann. Oncol. 35, S310\u2013S311 (2024).","journal-title":"Ann. Oncol."},{"key":"1120_CR136","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer \u2014 the Penelope-B trial. J. Clin. Oncol. 39, 1518\u20131530 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR137","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer, E. L. et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 22, 212\u2013222 (2021).","journal-title":"Lancet Oncol."},{"key":"1120_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103466","volume":"9","author":"F Marm\u00e9","year":"2024","unstructured":"Marm\u00e9, F. et al. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open\u00a09, 103466 (2024).","journal-title":"ESMO Open"},{"key":"1120_CR139","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","volume":"31","author":"J Garber","year":"2025","unstructured":"Garber, J. et al. OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer [abstract]. Clin. Cancer Res. 31, GS1-09 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR140","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clbc.2024.02.020","volume":"24","author":"X Jia","year":"2024","unstructured":"Jia, X., Wang, K., Zhuo, Q., Zhao, Z. & Li, M. PARP inhibitor for neoadjuvant therapy in HER2-negative breast cancer: a systematic review and meta-analysis of efficacy and safety. Clin. Breast Cancer 24, 392\u2013398.e3 (2024).","journal-title":"Clin. Breast Cancer"},{"key":"1120_CR141","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman, R. et al. Bone health in cancer: ESMO clinical practice guidelines. Ann. Oncol. 31, 1650\u20131663 (2020).","journal-title":"Ann. Oncol."},{"key":"1120_CR142","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro, C. L. et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J. Clin. Oncol. 37, 2916\u20132946 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR143","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro, C. L. et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur. J. Cancer 47, 683\u2013689 (2011).","journal-title":"Eur. J. Cancer"},{"key":"1120_CR144","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MFX Gnant","year":"2007","unstructured":"Gnant, M. F. X. et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 25, 820\u2013828 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR145","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9, 840\u2013849 (2008).","journal-title":"Lancet Oncol."},{"key":"1120_CR146","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis, G. K. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875\u20134882 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR147","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant, M. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386, 433\u2013443 (2015).","journal-title":"Lancet"},{"key":"1120_CR148","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.23.02309","volume":"42","author":"SK Ramchand","year":"2024","unstructured":"Ramchand, S. K. et al. Denosumab prevents bone loss and microarchitectural deterioration in premenopausal women with breast cancer receiving estradiol suppression therapy: a randomized controlled trial. J. Clin. Oncol. 42, 3466\u20133477 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR149","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386, 1353\u20131361 (2015).","journal-title":"Lancet"},{"key":"1120_CR150","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","volume":"1192","author":"KM Nicks","year":"2010","unstructured":"Nicks, K. M. et al. Bone turnover across the menopause transition the role of gonadal inhibins. Ann. N. Y. Acad. Sci. 1192, 153\u2013160 (2010).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1120_CR151","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200162","volume":"1","author":"M Gnant","year":"2022","unstructured":"Gnant, M. et al. Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evid. 1, EVIDoa2200162 (2022).","journal-title":"NEJM Evid."},{"key":"1120_CR152","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman, R. et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 21, 60\u201372 (2020).","journal-title":"Lancet Oncol."},{"key":"1120_CR153","unstructured":"Breast International Group. Optima Young. BIG https:\/\/bigagainstbreastcancer.org\/clinical-trials\/optima-young\/ (2026)."},{"key":"1120_CR154","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"1120_CR155","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"1120_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","volume":"3","author":"AL Winship","year":"2022","unstructured":"Winship, A. L. et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat. Cancer 3, 1\u201313 (2022).","journal-title":"Nat. Cancer"},{"key":"1120_CR157","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10549-025-07702-w","volume":"212","author":"A Perdrix","year":"2025","unstructured":"Perdrix, A. et al. Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy. Breast Cancer Res. Treat. 212, 79\u201386 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"1120_CR158","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","volume":"33","author":"I Vaz-Luis","year":"2022","unstructured":"Vaz-Luis, I. et al. ESMO expert consensus statements on cancer survivorship: promoting high-quality survivorship care and research in Europe. Ann. Oncol. 33, 1119\u20131133 (2022).","journal-title":"Ann. Oncol."},{"key":"1120_CR159","first-page":"43","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz, C. D. et al. American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J. Clin. 66, 43\u201373 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"1120_CR160","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0368-2242(59)80037-3","volume":"10","author":"R Paterson","year":"1959","unstructured":"Paterson, R. & Russell, M. H. Clinical trials in malignant disease: part II\u2014breast cancer: value of irradiation of the ovaries. J. Fac. Radiol. 10, 130\u2013133 (1959).","journal-title":"J. Fac. Radiol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01120-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:02:16Z","timestamp":1774443736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":160,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01120-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"8 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.-M. has received honoraria from and\/or has been an adviser for AstraZeneca, BMS, Gilead Sciences, MSD, Novartis, Pfizer and Roche; has received support for attending medical conferences from Amgen, AstraZeneca, BMS, Daiichi Sankyo, Gilead Sciences, Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi; and has participated as a medical research fellow in studies institutionally funded by AstraZeneca, F. Hoffmann-La Roche and Novartis. S.J.L. receives research funding to his institution from AstraZeneca, Beigene, Novartis, Roche and SpringWorks Therapeutics; and has received honoraria or consultation fees from AstraZeneca, Daiichi Sankyo and Novartis. M.P. is a member of the scientific board of Oncolytics; has received honoraria as a consultant from AstraZeneca, Gilead, Lilly, Menarini, Mersana, MSD, Novartis, Pfizer, Roche\u2013Genentech, Seattle Genetics, Seagen, NBE Therapeutics and Summit Therapeutics; and has received institutional research grants from AstraZeneca, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche\u2013Genentech and Servier. S.L. receives institutional research funding from AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Nektar Therapeutics, Novartis, Pfizer and Roche\u2013Genentech; has been a consultant for Adanate, Amaroq Therapeutics, AstraZeneca, Bicycle Therapeutics, BioNTech, BMS, Daiichi Sankyo, Domain Therapeutics, Eli Lilly, Exact Sciences, Gilead Sciences, MSD, Menari Asia-Pacific, Mersana Therapeutics, Novartis, Roche\u2013Genentech and SAGA Diagnostics. The disclosures from all the authors are outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}